2023 |
|||
Journal Articles |
|||
Nongodo Firmin Kaboré, Samiratou Ouédraogo, Ariane Kamga Mamguem, Isidore Tiandiogo Traoré, Dramane Kania, Hermann Badolo, Guillaume Sanou, Amariane Koné, Mimbouré Yara, Thérèse Kagoné, Esperance Ouédraogo, Blahima Konaté, Rachel Médah, Nathalie Rekeneire, Armel Poda, Arnaud Eric Diendéré, Boukary Ouédraogo, Oumar Billa, Gilles Paradis, Tienhan Sandrine Dabakuyo-Yonli, Halidou Tinto Incidence rate and predictors of COVID-19 in the two largest cities of Burkina Faso - prospective cohort study in 2021 (ANRS-COV13) Journal Article In: BMC infectious diseases, vol. 23, iss. 1, 2023, ISSN: 1471-2334. Abstract | BibTeX | Tags: Adult, Aged, Burkina Faso, Cities, COVID-19*, doi:10.1186/s12879-023-08361-2, Female, Halidou Tinto, Humans, Incidence, MEDLINE, Middle Aged, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Nongodo Firmin Kaboré, PMC10258776, pmid:37308819, Prospective Studies, PubMed Abstract, Samiratou Ouédraogo, SARS-Cov-2 | Links: @article{nokey, Background: Early data on COVID-19 (based primarily on PCR testing) indicated a low burden in Sub-Saharan Africa. To better understand this, this study aimed to estimate the incidence rate and identify predictors of SARS-CoV-2 seroconversion in the two largest cities of Burkina Faso. This study is part of the EmulCOVID-19 project (ANRS-COV13). Methods: Our study utilized the WHO Unity protocol for cohort sero-epidemiological studies of COVID-19 in general population. We conducted random sampling stratified by age group and sex. Individuals aged 10 years and older in the cities of Ouagadougou and Bobo-Dioulasso, Burkina Faso were included and surveyed at 4 time points, each 21 days apart, from March 3 to May 15, 2021. WANTAI SARS-CoV-2 Ab ELISA serological tests were used to detect total antibodies (IgM, IgG) in serum. Predictors were investigated using Cox proportional hazards regression. Results: We analyzed the data from 1399 participants (1051 in Ouagadougou, 348 in Bobo-Dioulasso) who were SARS-CoV-2 seronegative at baseline and had at least one follow-up visit. The incidence rate of SARS-CoV-2 seroconversion was 14.3 cases [95%CI 13.3–15.4] per 100 person-weeks. The incidence rate was almost three times higher in Ouagadougou than in Bobo-Dioulasso (Incidence rate ratio: IRR = 2.7 [2.2–3.2], p < 0.001). The highest incidence rate was reported among women aged 19–59 years in Ouagadougou (22.8 cases [19.6–26.4] per 100 person-weeks) and the lowest among participants aged 60 years and over in Bobo-Dioulasso, 6.3 cases [4.6–8.6] per 100 person-weeks. Multivariable analysis showed that participants aged 19 years and older were almost twice as likely to seroconvert during the study period compared with those aged 10 to 18 years (Hazard ratio: HR = 1.7 [1.3–2.3], p < 0.001). Those aged 10–18 years exhibited more asymptomatic forms than those aged 19 years and older, among those who achieved seroconversion (72.9% vs. 40.4%, p < 0.001). Conclusion: The spread of COVID-19 is more rapid in adults and in large cities. Strategies to control this pandemic in Burkina Faso, must take this into account. Adults living in large cities should be the priority targets for vaccination efforts against COVID-19. | |||
Samiratou Ouedraogo, Isidore Tiandiogo Traoré, Dramane Kania, Nongodo Firmin Kaboré, Ariane Mamguem Kamga, Hermann Badolo, Mimbouré Yara, Guillaume Sanou, Amariane Koné, Samdapawindé Thérèse Kagoné, Esperance Ouédraogo, Blahima Konaté, Rachel Médah, Nathalie Rekeneire, Armel Poda, Arnaud Eric Diendere, Boukary Ouédraogo, Oumar Billa, Gilles Paradis, Halidou Tinto, Tienhan Sandrine Dabakuyo-Yonli The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation Journal Article In: Influenza and other respiratory viruses, vol. 17, iss. 11, 2023, ISSN: 1750-2659. Abstract | BibTeX | Tags: Adolescent, Adult, Antibodies, Burkina Faso / epidemiology, Child, COVID-19* / epidemiology, doi:10.1111/irv.13216, Humans, Isidore Tiandiogo Traoré, MEDLINE, Middle Aged, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC10655778, pmid:38019697, PubMed Abstract, Samiratou Ouédraogo, SARS-CoV-2*, Seroepidemiologic Studies, Surveys and Questionnaires, Tienhan Sandrine Dabakuyo-Yonli, Viral | Links: @article{Ouedraogo2023, Background: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). Methods: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. Results: We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9–70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15–18 years old (74.2% [95% CI 70.5–77.5]) (N = 465/627), compared with those aged 10–14 years old (62.6% [95% CI 58.7–66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2–69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10–18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. Conclusion: This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19. |
Input your search keywords and press Enter.